Advertisement

Advances in Therapy

, Volume 27, Issue 11, pp 870–878 | Cite as

Hyaluronic acid improves “pleasantness” and tolerability of nebulized hypertonic saline in a cohort of patients with cystic fibrosis

  • Paolo BuonpensieroEmail author
  • Fabiola De Gregorio
  • Angela Sepe
  • Antonio Di Pasqua
  • Pasqualina Ferri
  • Maria Siano
  • Vito Terlizzi
  • Valeria Raia
Original Research

Abstract

Introduction

Inhaled hypertonic saline improves lung function and decreases pulmonary exacerbations in people with cystic fibrosis. However, side effects such as cough, narrowing of airways and saltiness cause intolerance of the therapy in 8% of patients. The aim of our study was to compare the effect of an inhaled solution of hyaluronic acid and hypertonic saline with hypertonic solution alone on safety and tolerability.

Methods

A total of 20 patients with cystic fibrosis aged 6 years and over received a single treatment regimen of 7% hypertonic saline solution or hypertonic solution with 0.1% hyaluronate for 2 days nonconsecutively after a washout period in an open crossover study. Cough, throat irritation, and salty taste were evaluated by a modified ordinal score for assessing tolerability; “pleasantness” was evaluated by a five-level, Likert-type scale. Forced expiratory volume in 1 second was registered before and after the end of the saline inhalations.

Results

All 20 patients (nine males, 11 females, mean age 13 years, range 8.9–17.7) completed the study. The inhaled solution of 0.1% hyaluronic acid and hypertonic saline significantly improved tolerability and pleasantness compared to hypertonic saline alone. No major adverse effects were observed. No difference was documented in pulmonary function tests between the two treatments.

Conclusion

Hyaluronic acid combined with hypertonic saline solution may contribute to improved adherence to hypertonic saline therapy. Further clinical trials are needed to confirm our findings. Considering the extraordinary versatility of hyaluronic acid in biological reactions, perspective studies could define its applicability to halting progression of lung disease in cystic fibrosis.

Keywords

cystic fibrosis hyaluronic acid hypertonic saline solution pleasantness tolerability 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    O’sullivan BP, Freedman SD. Cystic fibrosis. Lancet. 2009;373:1891–1904.CrossRefPubMedGoogle Scholar
  2. 2.
    Collins FS. Cystic fibrosis: molecular biology and therapeutic implications. Science. 1992;256:774–779.CrossRefPubMedGoogle Scholar
  3. 3.
    Welsh MJ, Smith AE. Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell. 1993;73:1251–1254.CrossRefPubMedGoogle Scholar
  4. 4.
    Boucher RC. Evidence for airway surface dehydration as the initiating event in CF airway disease. J Intern Med. 2007;261:5–16.CrossRefPubMedGoogle Scholar
  5. 5.
    Elkins MR, Robinson M, Rose BR, et al. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med. 2006;354:229–240.CrossRefPubMedGoogle Scholar
  6. 6.
    Subbarao P, Balkovec S, Solomon M, Ratjen F. Pilot study of safety and tolerability of inhaled hypertonic saline in infants with cystic fibrosis. Pediatr Pulmonol. 2007;42:471–476.CrossRefPubMedGoogle Scholar
  7. 7.
    Flume PA, O’sullivan BP, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med. 2007;176:957–969.CrossRefPubMedGoogle Scholar
  8. 8.
    Donaldson SH, Bennett WD, Zeman KL, Knowles MR, Tarran R, Boucher RC. Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N Engl J Med. 2006;354:241–250.CrossRefPubMedGoogle Scholar
  9. 9.
    Wark P, McDonald VM. Nebulised hypertonic saline for cystic fibrosis. Cochrane Database Syst Rev. 2009;15:CD001506.Google Scholar
  10. 10.
    Elkins MR, Bye PT. Inhaled hypertonic saline as a therapy for cystic fibrosis. Curr Opin Pulm Med. 2006;12:445–452.CrossRefPubMedGoogle Scholar
  11. 11.
    Rosenberg RC, Varma R. An overview of proteoglycans in physiology and pathology. In: Varma RS, Varma R, eds. Glycosaminoglycans and proteoglycans in physiological and pathological processes of body systems. Basel: Karger; 1982;1–4.Google Scholar
  12. 12.
    Scuri M, Abraham WM. Hyaluronan blocks human neutrophil elastase (HNE)-induced airway responses in sheep. Pulm Pharmacol Ther. 2003;16:335–340.CrossRefPubMedGoogle Scholar
  13. 13.
    Laurent TC. Structure of hyaluronic acid. In: Balazs EA, ed. Chemistry and molecular biology of the intercellular matrix. London: Academic Press; 1970;703–732.Google Scholar
  14. 14.
    Fraser JRE, Laurent TC, Laurent UBG. Hyaluronan: its nature, distribution, functions and turnover. J Intern Med. 1997;242:27–33.CrossRefPubMedGoogle Scholar
  15. 15.
    Holmes MWA, Bayliss MT, Muir H. Hyaluronic acid in human articular cartilage. Biochem J. 1988;250:435–441.PubMedGoogle Scholar
  16. 16.
    Nettelbladt O, Tengblad A, Hallgren R. Lung accumulation of hyaluronan parallels pulmonary edema in experimental alveolitis. Am J Physiol. 1989;257:L379–L384.PubMedGoogle Scholar
  17. 17.
    Schmid K, Grundboeck-Jusco J, Kimura A, et al. The distribution of the glycosamino- glycans in the anatomic components of the lung and the changes in concentration of these macromolecules during development and aging. Biochim Biophys Acta. 1982;716:178–187.PubMedGoogle Scholar
  18. 18.
    Turino GM, Cantor O. Hyaluronan in respiratory injury and repair. Am J Respir Crit Care Med. 2003;167:1169–1175.CrossRefPubMedGoogle Scholar
  19. 19.
    Venge P, Pedersen B, Hakansson L, Hallgren R, Lindblad G, Dahl R. Subcutaneous administration of hyaluronan reduces the number of infectious exacerbations in patients with chronic bronchitis. Am J Respir Crit Care Med. 1996;153:312–316.PubMedGoogle Scholar
  20. 20.
    Petrigni G, Allegra L. Aerosolised hyaluronic acid prevents exercise-induced bronchoconstrinction, suggesting novel hypotheses on the correction of matrix defects in asthma. Pul Pharmacol Ther. 2006;19:166–171.CrossRefGoogle Scholar
  21. 21.
    Kunz LI, van Rensen EL, Sterk PJ. Inhaled hyaluronic acid against exercise-induced bronchoconstriction in asthma. Pulm Pharmacol Ther. 2006;19:286–291.CrossRefPubMedGoogle Scholar
  22. 22.
    McIlwaine PM, Wong LT, Peacock D, Davidson AG. Long-term comparative trial of conventional postural drainage and percussion versus positive expiratory pressure physiotherapy in the treatment of cystic fibrosis. J Pediatr. 1997;131:570–574.CrossRefPubMedGoogle Scholar
  23. 23.
    Maurer JT, Pierce HR. A comparison of Likert scale and traditional measures of self-efficacy. J Appl Psychol. 1998;83:324–349.CrossRefGoogle Scholar

Copyright information

© Springer Healthcare 2010

Authors and Affiliations

  • Paolo Buonpensiero
    • 1
    Email author
  • Fabiola De Gregorio
    • 1
  • Angela Sepe
    • 1
  • Antonio Di Pasqua
    • 1
  • Pasqualina Ferri
    • 1
  • Maria Siano
    • 1
  • Vito Terlizzi
    • 1
  • Valeria Raia
    • 1
  1. 1.Department of PediatricsUniversity of Naples Federico IINaplesItaly

Personalised recommendations